Effects of somatostatin and pancreatic polypeptide on exocrine and endocrine pancreas in the rats.
The effects of somatostatin-14 (SS) and rat pancreatic polypeptide (rPP) on endocrine and exocrine functions of the pancreas, stimulated by 40 ng/kg cholecystokinin octapeptide during continuous infusion of 1 U/kg/h secretin, were investigated in the rat, in vivo. Protein output in the pancreatic juice and integrated insulin (IRI) secretion were inhibited, in a dose related fashion, by continuous infusion of SS, in doses of 0.5, 5 and 50 micrograms/100g/h. On the other hand, bicarbonate and volume output were not inhibited by SS. The rPP significantly inhibited not only the protein output but also the bicarbonate and volume output of the pancreatic juice in doses of 0.1 and 1 microgram/100g/h. Integrated IRI secretion was inhibited significantly by rPP, but the inhibition of IRI secretion was much greater in the portal than in the jugular vein. Plasma SS and rPP concentrations showed physiological ranges during infusion of doses of 0.5 and 0.1 microgram/100g/h of SS and rPP, respectively. Therefore, there was a marked difference between the inhibition by rPP and that by SS on the exocrine and endocrine pancreas. These observations suggest that SS and PP may play a physiological role in the pancreas and that their effects on the pancreas relate to different mechanisms.
D000818:Animals; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects*; D008297:Male; D010179:Pancreas / Q000187:drug effects*; D010189:Pancreatic Juice / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000494:pharmacology*; D051381:Rats; D012844:Sincalide / Q000494:pharmacology; D013004:Somatostatin / Q000494:pharmacology*
D007328:Insulin; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D012844:Sincalide